OSIRAM-1/TORG1833: Overall Survival Results of a Randomized Phase II Study of Osimertinib Plus Ramucirumab Versus Osimertinib Alone As Initial Chemotherapy for EGFR Mutation-Positive Non-Squamous Non-Small Cell Lung Cancer.